A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)-Reference-Cited by-同舟云学术

A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)

Published:2020-10-04 Issue:12 Volume:50 Page:1342-1351
ISSN:0954-7894
Container-title:Clinical & Experimental Allergy
language:en
Short-container-title:Clin Exp Allergy

Author:

Austin Cary D.¹^ORCID,Gonzalez Edick Melissa¹,Ferrando Ronald E.¹,Solon Margaret¹,Baca Miriam¹,Mesh Kathryn¹,Bradding Peter²,Gauvreau Gail M.³^ORCID,Sumino Kaharu⁴,FitzGerald J. Mark⁵,Israel Elliot⁶,Bjermer Lief⁷,Bourdin Arnaud⁸^ORCID,Arron Joseph R.¹,Choy David F.¹,Olsson Julie K.¹,Abreu Francis¹,Howard Monet¹,Wong Kit¹,Cai Fang¹,Peng Kun¹,Putnam Wendy S.¹,Holweg Cécile T.J.¹,Matthews John G.¹,Kraft Monica⁹,Woodruff Prescott G.¹⁰,

Affiliation:

1. Genentech, Inc. South San Francisco CA USA

2. University of Leicester and Glenfield Hospital Leicester UK

3. McMaster University Hamilton ON Canada

4. Washington University School of Medicine in St. Louis St Louis MO USA

5. University of British Columbia Vancouver BC Canada

6. Brigham and Women’s Hospital Boston MA USA

7. Skåne University Hospital Lund Sweden

8. CHU de Montpellier Montpellier France

9. University of Arizona College of Medicine Tucson AZ USA

10. San Francisco Medical Center University of California San Francisco CA USA

Publisher